Xellar Biosystems

Xellar Biosystems has developed the world's first pharmaceutical-scale organ-on-chip platform, combining high-throughput screening with advanced image-based AI to enable more predictive drug discovery while reducing reliance on animal testing. The company's four-core E.P.I.C. platform integrates microfluidic chip engineering, pharma-scale drug testing, high-content 3D imaging, and an AI computation pipeline in a closed-loop feedback cycle that delivers 90% predictive accuracy versus 50-65% with live animals. Xellar partners with pharmaceutical leaders including Sanofi to develop organ-on-chip models for vascular toxicity and other preclinical applications.